FindTrial
Sign In

JAB-3312

DRUG5 trials

Sponsors

Jacobio Pharmaceuticals Co., Ltd., Allist Pharmaceuticals, Inc.

Conditions

Advanced Non-squamous Non-small-cell Lung CancerBreast CancerColorectal CancerEsophageal Squamous Cell CarcinomaHead and Neck Squamous Cell CarcinomaKRAS P.G12CMetastatic Non-squamous Non Small Cell Lung CancerNSCLC

Phase 1

A First-in-Human, Phase 1 Study of JAB-3312 in Adult Patients With Advanced Solid Tumors
CompletedNCT04045496
Jacobio Pharmaceuticals Co., Ltd.Breast Cancer, Colorectal Cancer, Esophageal Squamous Cell Carcinoma +4
Start: 2019-09-26End: 2022-12-16Updated: 2025-12-29
A Study of JAB-3312 in Adult Patients With Advanced Solid Tumors in China
CompletedNCT04121286
Allist Pharmaceuticals, Inc.Breast Cancer, Colorectal Cancer, Esophageal Squamous Cell Carcinoma +4
Start: 2020-07-14End: 2022-06-17Updated: 2025-05-20
JAB-3312 Based Combination Therapy in Adult Patients With Advanced Solid Tumors
CompletedNCT04720976
Allist Pharmaceuticals, Inc.NSCLC, Solid Tumor
Start: 2021-03-23End: 2023-12-19Updated: 2025-04-11
Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation
RecruitingNCT05288205
Allist Pharmaceuticals, Inc.Colorectal Cancer, KRAS P.G12C, Non-small Cell Lung Cancer +1
Start: 2022-04-14End: 2027-03-01Target: 240Updated: 2026-08-13

Phase 3

JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation
RecruitingNCT06416410
Allist Pharmaceuticals, Inc.Advanced Non-squamous Non-small-cell Lung Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer
Start: 2024-08-07End: 2030-08-01Target: 392Updated: 2026-08-13

Related Papers

Glecirasib plus sitneprotafib in patients with KRAS<sup>G12C</sup>-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 1/2a trial.
2025-11-28
JAB-3312, a Potent Allosteric SHP2 Inhibitor That Enhances the Efficacy of RTK/RAS/MAPK and PD-1 Blockade Therapies
Clinical Cancer Research2025-05-073 citations
Glecirasib, a Potent and Selective Covalent KRAS G12C Inhibitor Exhibiting Synergism with Cetuximab or SHP2 Inhibitor JAB-3312
Cancer Research Communications2025-04-303 citations
Updated safety and efficacy data of combined KRAS G12C inhibitor (glecirasib, JAB-21822) and SHP2 inhibitor (JAB-3312) in patients with <i>KRAS p.G12C</i> mutated solid tumors.
Journal of Clinical Oncology2024-06-0117 citations